-

Curio Bioscience Responds to Lawsuit

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience is a leading innovator of high-precision tools for the life sciences industry. Our Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution and represents the next stage of innovation from our team's inventions of the microarray, stochastic barcoding (unique molecular identifiers), and single cell and spatial tagging and analysis. Our team's inventions of spatial localization of biological targets using barcoding were documented over 15 years ago.

We believe that fair competition is a key component to innovation, and we embrace the motivation that it provides for creating the newest and highest-performing products for our customers, while keeping experiment costs reasonable and pushing the frontiers of science to the greatest extent possible.

Some companies do not share this sentiment. We have become the latest target in a string of attacks by a company (10x Genomics, NASDAQ: TXG) with a history of bringing litigation against smaller, innovating companies.

We are confident that we do not infringe the patents that 10x is asserting against us and believe that they will be found invalid. We will vigorously defend against 10x’s allegations.

Contacts

info@curiobioscience.com

Industry:

Curio Bioscience

Release Versions
English

Contacts

info@curiobioscience.com

More News From Curio Bioscience

Curio Bioscience Launches Trekker Single-Cell Spatial Mapping Kit

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience today announced the worldwide availability of Curio Trekker, a new single-cell spatial mapping kit that converts single-cell genomics measurements into tissue-specific spatial data. More than 80 early access customers have already validated this powerful new tool to advance discovery research in cancer biology, neuroscience, developmental sciences and beyond. Making spatial omics more accessible, Curio Trekker delivers true single-cell spatia...

Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made. The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ: TXG). The UPC has also ordered Curio Bioscience not to offer any product that would violate claim 14 of the ‘391 patent in France, Germany, and...

Curio Bioscience Announces Early Access to the World’s First Product to Transform Single-Cell Sequencing Data into Spatial Context

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience today announced the commercialization of the world’s first technology that spatially contextualizes single-cell sequencing data, leveraging a breakthrough invention called Slide-tags developed by the Broad Institute of MIT and Harvard and published in Nature this past December. The first stage of Curio’s commercialization of this new product, called Curio Trekker, is an early access program that already includes world-class research organizat...
Back to Newsroom